Trelegy Ellipta approved as first once-daily single inhaler triple therapy
GlaxoSmithKline and Innoviva announced the FDA has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol , under the brand name Trelegy Ellipta, for long-term, once-daily, maintenance treatment of patients with COPD. September 18, 2017